Cardiotoxicity induced by multiple myeloma therapies: mechanistic convergence across proteasome inhibitors, CAR-T, and bispecific antibodies.
Understanding how modern blood cancer drugs damage the heart reveals shared pathways, enabling doctors to design better surveillance and prevention strategies.
This comprehensive review from MD Anderson synthesizes cardiotoxicity mechanisms across all major modern multiple myeloma therapy classes (proteasome inhibitors, CAR-T, bispecific antibodies), identifying mitochondrial dysfunction, unfolded protein response, and endothelial injury as convergent pathways. The review highlights the need for personalized cardio-oncology protocols with integrated biomarker surveillance for the growing MM survivor population.
What the study was
- Study design
- Narrative/systematic review
- Population
- Multiple myeloma patients on modern therapies (literature-based; MD Anderson)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Blood cancer journal
Why it surfaced
Clinically relevant review for MM prescribers on cross-therapy cardiotoxicity; useful for cardio-oncology protocol development. Review design limits score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.